Virtual Library

Start Your Search

R. Zhong

Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P107 - The Study of Relationship Between Tumor Burden (TMB) and Molecular Typing of Non-Small Cell Lung Cancer (NSCLC) (ID 127)

      00:00 - 00:00  |  Author(s): R. Zhong

      • Abstract

      Tumor mutation burden (TMB) is one of the strongest biomarker to stratify patients suitable for immunotherapy. However, the relationship between TMB and other typical genetic profile in lung adenocarcinoma is not clear. This study aimed to explore the genetic characteristics of non-small cell lung cancer (NSCLC) relationship between TMB and typical genetic profile in NSCLC patients.

      Tumor tissue from 11 NSCLC patients in Jilin Cancer Hospital from July 2018 to August 2018 were tested by next generation sequencing (>500 target gene panel). 10 mutations/1 M basepairs as cut-off value, patients were divided into high tumor butden (TMB-High) and low tumor burden (TMB-Low). TMB relationship with lung cancer core genes (EGFR, ALK, ROS1, KRAS, BRAF, MET, RET and ERBB2), tumor suppressor genes, proto-oncogenes, and MSI was statistically analyzed.

      Among the 11 NSCLC patients, 45% (5/11) of patients were TMB-low and 55% (6/11) of patients were TMB- high. 100% (11/11) of patients were microsatellite Stable (MSS) and there were no MSI patients. In TMB-low patients, there were 14 mutations in 9 tumor suppressor genes and 1 mutation in 1 proto-oncogene; 40% (2/5) of these patients had TP53 mutations; 60% (3/5) of these patients had 5 mutations in 4 lung cancer core genes (EGFR, MET, KRAS and ROS1). In TMB-high patients, there were 29 mutations in 17 tumor suppressor genes, 8 mutations in 4 proto-oncogenes; 100% (6/6) of these patients had TP53 mutations.; 83% (5/6) of these patients had 9 mutations in 4 lung cancer core genes.

      Compared with TMB-high, TMB-low patients have less number of tumor suppressor genes, proto-oncogene mutations, TP53 mutations and lung cancer core gene mutations In addition, TMB may not be associated with MSI. This study could further understand the genetic characteristics of NSCLC and provide new theoretical basis for immunotherapy for NSCLC.